Frontiers in Neurology (Nov 2022)

The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement

  • Sylvia Raftopoulou,
  • Anna Rapti,
  • Dimitris Karathanasis,
  • Maria Eleftheria Evangelopoulos,
  • Clio P. Mavragani

DOI
https://doi.org/10.3389/fneur.2022.1026449
Journal volume & issue
Vol. 13

Abstract

Read online

Type I interferons (IFNs) are major mediators of innate immunity, with well-known antiviral, antiproliferative, and immunomodulatory properties. A growing body of evidence suggests the involvement of type I IFNs in the pathogenesis of central nervous system (CNS) manifestations in the setting of chronic autoimmune and autoinflammatory disorders, while IFN-β has been for years, a well-established therapeutic modality for multiple sclerosis (MS). In the present review, we summarize the current evidence on the mechanisms of type I IFN production by CNS cellular populations as well as its local effects on the CNS. Additionally, the beneficial effects of IFN-β in the pathophysiology of MS are discussed, along with the contributory role of type I IFNs in the pathogenesis of neuropsychiatric lupus erythematosus and type I interferonopathies.

Keywords